上交所对宁夏中科生物科技股份有限公司及实际控制人虞建明和有关责任人予以纪律处分

Group 1: Company Violations - Ningxia Zhongke Biotechnology Co., Ltd. (ST Ningke) reported false records in its 2022 annual report, inflating revenue by 76.5941 million yuan and profit by 77.222 million yuan, which accounted for 11.25% and 46.59% of total revenue and profit respectively [2][3] - The company failed to timely disclose significant debts, with a total borrowing balance of 108 million yuan as of December 9, 2022, representing 11.82% of the audited net assets for 2021, and 64.26 million yuan as of September 14, 2023, representing 10.88% of the audited net assets for 2022 [3][4] - The company provided guarantees without following decision-making procedures and disclosure obligations, signing a pledge contract with Guangdong Nanyue Bank for loans up to 486.9 million yuan without proper disclosure in the 2022 annual report [4][5] Group 2: Responsibility and Disciplinary Actions - The actual controller, Yu Jianming, was found to have organized and directed the financial fraud, leading to the false records in the annual report [6] - Key executives including Huang Haisu (Chairman), Chen Rui (General Manager), and Dong Chunxiang (CFO) were directly responsible for the violations, failing to fulfill their duties and allowing the fraudulent activities to occur [6][7] - The Shanghai Stock Exchange issued public reprimands to the company and involved individuals, including a six-year disqualification for Yu Jianming from holding any positions in listed companies [11][12] Group 3: Company Operations and Financials - As of the latest report, ST Ningke had a market capitalization of 3.3 billion yuan [14] - The company's revenue composition for 2024 indicated that 64.0% came from chemical raw materials and chemical products manufacturing, while 35.26% was from bio-based and starch-based new materials [12]